# 510(k) Summary

# Tosoh Bioscience, Inc.'s Automated Glycohemoglobin Analyzer HLC-723G8

# Submitter:

Tosoh Bioscience, Inc 3600 Gantz Road Grove City, OH 43123

# Contact Person:

Robert L. Wick   
Regulatory Specialist   
6000 Shoreline Ct., Ste. 101   
South San Francisco, CA 94080   
Phone: 650-636-8117   
Fax: 650-636-8121   
Email: Robert.Wick@Tosoh.com

Device Name: Classification Name:

Automated Glycohemoglobin Analyzer HLC-723G8   
Hemoglobin A1c Test System   
Class II   
PDJ   
21 CFR 862.1373

Predicate Device:

K121291   
Roche Diagnostics Corporation   
COBAS INTEGRA 800 Tina-quant HbA1cDx Gen.2   
assay

# 510(k) Summary

# Automated Glycohemoglobin Analyzer HLC-723G8

Accrdin e eent  CR 079, e oa vi detail to understand the basis for a determination of substantial equivalence.

# Device Description:

The Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 is an automated High Performance Liquid Chromatography (HPLC) system that separates and reports stable Alc (sA1c) percentage in whole blood The operational portion of the G8 is composed of a sampling unit, liquid pump, degasser, column, detector, microprocessors, sample loader, floppy disk drive unit, operation panel and a printer.

The Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 uses non-porous ion- exchange high performance liquid chromatography (HPLC) for rapid, accurate and precise separation of the stable form of HbA 1c from other hemoglobin fractions. The G8 uses a cation exchange column and separates the usual hemoglobin components in the blood into six fractions, Ala, A1b, F, LAlc, sA lc, and A0. The separation is done by eluting the hemoglobins from the column with a stepwise elution of three elution buffers containing different salt concentrations. The result report includes a sample ID, date, percentage and retention time of each fraction, sA 1c percentage and total A1 percentage $( \mathsf { A } \mathsf { l a } + \mathsf { A } \mathsf { l b } + \mathsf { s A } \mathsf { l c } _ { . }$ , along with a chromatogram of the elution pattern of the hemoglobin fractions. If a sample contains a hemoglobin variant, the column elutes the material depending upon its charge.

# New Device Intended Use:

The Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 is intended for in vitro diagnostic use for the quantitative measurement of $\%$ hemoglobin A1c (HbA1c) (DCCT/NGSP) and mmol/mo hemoglobin A1c (IFCC) in whole blood specimens. This test is to be used as an aid in diagnosis of diabetes and as an aid in identifying patients who may be at risk for developing diabetes.

# Substantial Equivalence: Comparison between the Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 and - the COBAS INTEGRA 800 Tina-quant HbA1cDx Gen.2 assay

# Similarities

<table><tr><td></td><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Tosoh AutomatedGlycohemoglobin AnalyzerHLC-723G8 (k)071132(k)131580</td><td rowspan=1 colspan=1>COBAS INTEGRA 800Tina-quantHbA1cDx Gen.2 assay(k)121291</td></tr><tr><td></td><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Tosoh AutomatedGlycohemoglobin AnalyzerHLC-723G8 is intended for invitro diagnostic use for themeasurement of hemoglobinAlc (HbA 1c) in whole bloodspecimens. Hemoglobin A lcmeasurements are used in theclinical management ofdiabetes to assess the long-term efficacy of diabeticcontrol. This test is to be usedas an aid in diagnosis ofdiabetes and identifyingpatients who may be at risk fordeveloping diabetes.</td><td rowspan=1 colspan=1>This test is to be used as an aidin diagnosis of diabetes and asan aid in identifying patientswho may be at risk fordeveloping diabetes TheCOBAS INTEGRA 800 Tina-quant HbA IcDx Gen.2 assayis an in vitro diagnosticsreagent system intended forquantitative determination ofmmol/mol hemoglobin Alc(IFCC) and % hemoglobinA1c (DCCT/NGSP) inhemolysate or whole blood onthe Roche COBAS INTEGRA800 clinical chemistryanalyzer</td></tr><tr><td></td><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human Whole Blood</td><td rowspan=1 colspan=1>Human Whole Blood</td></tr><tr><td></td><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>EDTA Whole Blood</td><td rowspan=1 colspan=1>EDTA, Li-Heparin, NaHeparin, NaF/K- Oxalate</td></tr><tr><td></td><td rowspan=1 colspan=1>Standardization</td><td rowspan=1 colspan=1>Certified via the NationalGlycohemoglobinStandardizationProgram (NGSP)</td><td rowspan=1 colspan=1>Certified via the NationalGlycohemoglobinStandardizationProgram (NGSP)</td></tr><tr><td></td><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>Linearity was previouslyevaluated for this assay underk071132. The reportablerange is 4.0% - 16.9%.</td><td rowspan=1 colspan=1>Linearity was previouslyevaluated for this assay underk072714. The reportablerange is 4.2-20.1%</td></tr><tr><td rowspan=1 colspan=2>Interference</td><td rowspan=1 colspan=1>Substances were evaluated attwo HbA 1c levels (6.5% and≥8% HbA1c)LipemiaConjugated BilirubinUnconjugated bilirubinRheumatoid FactorGlucoseTotal ProteinAscorbic AcidAcetylsalicylic Acid</td><td rowspan=1 colspan=1>Substances were evaluated attwo HbA 1c levels (~6.5 and~8.9% HbAIc)LipemiaConjugated BilirubinUnconjugated bilirubinRheumatoid FactorGlucoseTotal ProteinAscorbic AcidAcetylsalicylic Acid</td></tr></table>

Tosoh Bioscience, Inc.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Acetaldehyde</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>HbA lc concentration values ofapproximately 5%, 6.5%, 8%and 12%Precision was determined tobe 0.7 - 1.8% (total precision)and 0.3 - 0.9% (within run,precision).</td><td rowspan=1 colspan=1>HbA lc concentration values ofapproximately 5%, 6.5%, 8%and 10%The between-analyzer andbetween-lot precision wasequal to or less than 1.5% forconcentrations in the range of5.3% to 12.1% HbA1c</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin VariantInterference</td><td rowspan=1 colspan=1>HbA2, HbS, HbC, HbD, doesnot interfere with the assay.</td><td rowspan=1 colspan=1>HbA2, HbS, HbC, HbD, doesnot interfere with the assay.</td></tr><tr><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>Concentration and Bias:6.0% -0.847%6.5% -0.753%7.0% -0.673%</td><td rowspan=1 colspan=1>Concentration and Bias:5.2% 1.21%6.5% 1.29%8.0% 1.34%</td></tr><tr><td rowspan=1 colspan=1>Total Error - allowable bias6%</td><td rowspan=1 colspan=1>Concentration and Total Error5.05.8%6.5 2.8%8.03.0%12.0 3.1%</td><td rowspan=1 colspan=1>Concentration and Total Error5.24.2%6.5 4.1%8.04.1%</td></tr></table>

# Differences

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Tosoh AutomatedGlycohemoglobin AnalyzerHLC-723G8 (k)071132</td><td rowspan=1 colspan=1>COBAS INTEGRA 800Tina-quantHbA1cDx Gen.2 assay(k)121291</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>Ion-exchange HPLC</td><td rowspan=1 colspan=1>Quantitative turbidimetricinhibition immunoassay</td></tr><tr><td rowspan=1 colspan=1>Detection Method</td><td rowspan=1 colspan=1>Visible wavelength detector</td><td rowspan=1 colspan=1>Absorption spectrum andmeasured biochromatically.</td></tr><tr><td rowspan=1 colspan=1>Method Comparison</td><td rowspan=1 colspan=1>The method comparison studywas conducted utilizing theAutomated GlycohemoglobinAnalyzer HLC-723G8 and thePrimus model ultra2.r = 0.991(Y = 0.996x + 0.073)</td><td rowspan=1 colspan=1>The method comparison studywas conducted using utilizingthe Roche COBAS INTEGRA800 Tina-quant HbA1cDxGen.2 assay and the TosohAutomated GlycohemoglobinAnalyzer HLC-723G8.r = None Listed(Y = 1.015x + 0.015)</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin VariantInterference</td><td rowspan=1 colspan=1>HbE does interfere with theassay.</td><td rowspan=1 colspan=1>HbF does interfere with theassay.</td></tr></table>

Tosoh Bioscience, Inc.

# PERFORMANCE CHARACTERISTICS

# Interference:

Ths interference study was develope according to the CLS guideline Inteference Tesn Clinical Chemistry (EP7-A2).

Interference studies were conducted on known concentrations of HbA 1c. They were spiked with increasing amounts of the substances below. Interference was determined as a variance greater than the assigned value x $1 . 0 0 \pm 5 \%$ .

<table><tr><td rowspan=1 colspan=1>PotentialInterferent</td><td rowspan=1 colspan=1>Range tested</td><td rowspan=1 colspan=1>%A1cConcentrations</td><td rowspan=1 colspan=1>Concentration in whichno significantinterference wasobserved</td></tr><tr><td rowspan=1 colspan=1>Acetylated Hb</td><td rowspan=1 colspan=1>10 - 50 mg/dL</td><td rowspan=1 colspan=1>6.5 and 9.5</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>500 - 5000 mg/dL</td><td rowspan=1 colspan=1>6.6 and 14.7</td><td rowspan=1 colspan=1>5000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Aldehyde Hb</td><td rowspan=1 colspan=1>5.0 - 25 mg/dL</td><td rowspan=1 colspan=1>6.3 and 12.6</td><td rowspan=1 colspan=1>25 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>3.0 - 25 mg/dL</td><td rowspan=1 colspan=1>6.4 and 10.8</td><td rowspan=1 colspan=1>25 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Carbamylated Hb</td><td rowspan=1 colspan=1>5.0 - 25 mg/dL</td><td rowspan=1 colspan=1>6.5 and 9.8</td><td rowspan=1 colspan=1>25 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilrubin C</td><td rowspan=1 colspan=1>2.0 - 21 mg/dL</td><td rowspan=1 colspan=1>6.5 and 14.3</td><td rowspan=1 colspan=1>21 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Labile Hb</td><td rowspan=1 colspan=1>200 - 1000 mg/dL</td><td rowspan=1 colspan=1>6.4 and 10.3</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>100 - 1000 mg/dL</td><td rowspan=1 colspan=1>6.4 and 14.1</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>1 10 - 550 IU/mL</td><td rowspan=1 colspan=1>6.3 and 12.6</td><td rowspan=1 colspan=1>550 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin F </td><td rowspan=1 colspan=1>2.0 - 18 mg/dL</td><td rowspan=1 colspan=1>6.5 and 14.3</td><td rowspan=1 colspan=1>18 mg/dL</td></tr></table>

Tosoh Bioscience, Inc.

# Hemoglobin Variant Interference study

<table><tr><td rowspan=1 colspan=1>HemoglobinVariant</td><td rowspan=1 colspan=1>Number ofSamples atapproximately6% and ≥8%</td><td rowspan=1 colspan=1>%HbAlcreference values</td><td rowspan=1 colspan=1>x IFCCmmol/ml</td><td rowspan=1 colspan=1>% Variant·1</td><td rowspan=1 colspan=1>Interference</td></tr><tr><td rowspan=2 colspan=1>HbS</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>36.42</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>10.</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>78.1</td><td rowspan=1 colspan=1>29.49</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=2 colspan=1>HbC</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>36.54</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>59.4</td><td rowspan=1 colspan=1>35.06</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=2 colspan=1>HbE*</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=2 colspan=1>HbD</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>43.1</td><td rowspan=1 colspan=1>36.23</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>66.9</td><td rowspan=1 colspan=1>35.70</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=2 colspan=1>HbF</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>56.5</td><td rowspan=1 colspan=1>24.38</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>7.43</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=2 colspan=1>HbA2</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6.59</td><td rowspan=1 colspan=1>47.1</td><td rowspan=1 colspan=1>13.9</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.05</td><td rowspan=1 colspan=1>62.9</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>No</td></tr></table>

as ow Ene Whe p s    E will be displayed. The $\%$ HbA lc result will not be reportd fom the analyzer.

The Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 has known Hemoglobin E (HbE) interference. When a sample is suspected to contain HbE a flag will be displayed. The HbA1c result will not be reported from the analyzer.

The percent relative bias from the reference method at low and high concentrations of %HbA lc in each sample is:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Percent Relative Bias from Reference Methodat Low and High Concentrations of %HbA 1c.Samples</td></tr><tr><td rowspan=1 colspan=1>Hb Variant</td><td rowspan=1 colspan=1>~6.5 %HbA 1c</td><td rowspan=1 colspan=1>≥8 %HbA1c</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-5</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>-5</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>*Flag</td><td rowspan=1 colspan=1>*Flag</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>-3</td></tr><tr><td rowspan=1 colspan=1>A2</td><td rowspan=1 colspan=1>-2</td><td rowspan=1 colspan=1>-2</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td></tr></table>

# Precision:

The precision study was developed with reference to the CLSI protocol entitled: Evaluation of Precision Performance of Quantitative Measurement Methods (EP5-A2).

Tosoh Bioscience, Inc.

Precision was assessed by assaying four concentrations of unaltered EDTA whole blood specimens with each using 3 lots and 3 instruments. Estimates of total and within-run precision were obtained from measurements of 2 replicates in a single run, 2 times a day for 20 nonconsecutive days for each specimen/reagent combination. This equaled a total of 40 runs and 80 determinants for each data set. There were three (3) data sets at HbA 1c concentrations of approximately $5 \%$ $6 . 5 \%$ $8 \%$ and $12 \%$ for each specimen.

# Within-run Precision

Intra-assay (within run) Precision

<table><tr><td></td><td>Mean</td><td>Standard Deviation</td><td>Coefficient of Variation</td></tr><tr><td>Sample EDTA Whole Blood 5% AI</td><td>(%) 4.98</td><td>(%) 0.04</td><td>(%) 0.86</td></tr><tr><td>EDTA Whole Blood 5% A2</td><td>5.00</td><td>0.05</td><td>1.00</td></tr><tr><td>EDTA Whole Blood 5% A3</td><td>4.93</td><td>0.03</td><td>0.68</td></tr><tr><td>EDTA Whole Blood 6.5% B1</td><td>6.50</td><td>0.02</td><td>0.29</td></tr><tr><td>EDTA Whole Blood 6.5% B2</td><td>6.51</td><td>0.02</td><td>0.35</td></tr><tr><td>EDTA Whole Blood 6.5% B3</td><td>6.44</td><td>0.03</td><td>0.44</td></tr><tr><td>EDTA Whole Blood 8% CI</td><td>7.89</td><td>0.02</td><td>0.26</td></tr><tr><td>EDTA Whole Blood 8% C2</td><td>7.90</td><td>0.03</td><td>0.32</td></tr><tr><td>EDTA Whole Blood 8% C3</td><td>7.81</td><td>0.03</td><td>0.34</td></tr><tr><td>EDTA Whole Blood 12% DI</td><td>11.90</td><td>0.02</td><td>0.18</td></tr><tr><td>EDTA Whole Blood 12% D2</td><td>11.89</td><td>0.03</td><td>0.23</td></tr><tr><td>EDTA Whole Blood 12% D3</td><td>11.79</td><td>0.03</td><td>0.27</td></tr></table>

# Total Precision

<table><tr><td></td><td>Mean</td><td>Standard Deviation</td><td>Coefficient of Variation</td></tr><tr><td>Sample</td><td>(%)</td><td>(%)</td><td>(%)</td></tr><tr><td>EDTA Whole Blood 5% A1</td><td>4.98</td><td>0.09</td><td>1.83</td></tr><tr><td>EDTA Whole Blood 5% A2</td><td>5.00</td><td>0.09</td><td>1.79</td></tr><tr><td>EDTA Whole Blood 5% A3</td><td>4.93</td><td>0.08</td><td>1.69</td></tr><tr><td>EDTA Whole Blood 6.5% Bl</td><td>6.50</td><td>0.04</td><td>0.68</td></tr><tr><td>EDTA Whole Blood 6.5% B2</td><td>6.51</td><td>0.07</td><td>1.14</td></tr><tr><td>EDTA Whole Blood 6.5% B3</td><td>6.44</td><td>0.07</td><td>1.10</td></tr><tr><td>EDTA Whole Blood 8% C1</td><td>7.89</td><td>0.08</td><td>0.98</td></tr><tr><td>EDTA Whole Blood 8% C2</td><td>7.90</td><td>0.07</td><td>0.89</td></tr><tr><td>EDTA Whole Blood 8% C3</td><td>7.81</td><td>0.07</td><td>0.86</td></tr><tr><td>EDTA Whole Blood 12% D1</td><td>11.90</td><td>0.16</td><td>1.31</td></tr><tr><td>EDTA Whole Blood 12% D2</td><td>11.89</td><td>0.19</td><td>1.58</td></tr><tr><td>EDTA Whole Blood 12% D3</td><td>11.79</td><td>0.13</td><td>1.14</td></tr></table>

Tosoh Bioscience, Inc.

# Correlation:

The methods comparison study was conducted with reference to the CLSl protocol entitled: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (EP9-A2- IR).

Comparative testing was conducted between samples which were analyzed on the Automated Glycohemoglobin Analyzer HLC-723G8 (candidate method) and Primus ultra2 (comparative method) analyzed by a secondary NGSP reference laboratory.

A total of 120 unaltered EDTA whole blood specimens were assayed in singleton. Frozen specimens were utilized for this study. The sample distribution is as follows:

<table><tr><td rowspan=1 colspan=1>Hemoglobin Alc level</td><td rowspan=1 colspan=1>Number of samplestested at each A l cLevel</td><td rowspan=1 colspan=1>%samples tested</td></tr><tr><td rowspan=1 colspan=1>≤ 5%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4.2%</td></tr><tr><td rowspan=1 colspan=1>5 - 6%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>12.5%</td></tr><tr><td rowspan=1 colspan=1>6-6.5%</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>25.0%</td></tr><tr><td rowspan=1 colspan=1>6.5- 7%</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>25.0%</td></tr><tr><td rowspan=1 colspan=1>7-8%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>16.7%</td></tr><tr><td rowspan=1 colspan=1>8-9%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>&gt; 9%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>Total samples</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>100%</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Regression Analysis</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Deming</td><td rowspan=1 colspan=1>Regular</td></tr><tr><td rowspan=1 colspan=1>Slope:</td><td rowspan=1 colspan=1>0.996 (0.971 to 1.021)</td><td rowspan=1 colspan=1>0.987 (0.962 to 1.012)</td></tr><tr><td rowspan=1 colspan=1>Intercept:</td><td rowspan=1 colspan=1>0.073 (-0.110 to 0.255)</td><td rowspan=1 colspan=1>0.139 (-0.043 to 0.321)</td></tr><tr><td rowspan=1 colspan=1>Corr Coef (R):</td><td rowspan=1 colspan=2>0.991</td></tr><tr><td rowspan=1 colspan=1>Bias:</td><td rowspan=1 colspan=2>0.047 (0.657 %)</td></tr><tr><td rowspan=1 colspan=1>Points(Plotted/Total):</td><td rowspan=1 colspan=2>120/120</td></tr><tr><td rowspan=1 colspan=1>Result Ranges:</td><td rowspan=1 colspan=2>4.50% to 16.5%</td></tr></table>

# Total Error Near the Cutoff

Using the results of bias estimation (%Bias) in the method comparison study and precision estimates in the precision study, Total Error (TE) at four concentrations: $( 5 . 0 \% , 6 . 5 \%$ $8 . 0 \%$ and 12.0) was calculated as follows: $\% \mathrm { { T E } = 1 9 6 B i a s | + 1 . 9 6 ~ ^ { * } \% C V ^ { * } ( 1 + \% B i a s ) }$ The results are presented in the tables below. $\% \mathrm { T E }$ of $6 \%$ is acceptable.

<table><tr><td rowspan=1 colspan=1>Decision Level %</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0.</td><td rowspan=1 colspan=1>[1.08</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>2.8</td></tr></table>

# Automated Glycohemoglobin Analyzer HLC-723G8

Tosoh Bioscience, Inc.

<table><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>3.1</td></tr></table>

Using the calculation: $( \mathrm { T E } ) _ { 9 5 } = \mathrm { B i a s } + 1 . 9 6 ^ { * } \mathrm { S D }$ the result e hown in theollwingle:

<table><tr><td rowspan=1 colspan=1>Decision Level %</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>(TE)95</td><td rowspan=1 colspan=1>Goal at 6%</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.30</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.39</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.48</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>0.72</td></tr></table>

![](images/2e2e9e18e13c8c1a6085178a89812452894e3e44f37c5e6e814b0c4953bb13ca.jpg)

Standards:   

<table><tr><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=1>FDARecognitionNumber</td><td rowspan=1 colspan=1>RevisionDate</td><td rowspan=1 colspan=1>Title</td></tr><tr><td rowspan=1 colspan=1>EP5-A2</td><td rowspan=1 colspan=1>7-110</td><td rowspan=1 colspan=1>10/31/2005</td><td rowspan=1 colspan=1>Evaluation of Precision Performance ofQuantitative Measurement Methods: ApprovedGuideline- Second Edition</td></tr><tr><td rowspan=1 colspan=1>EP09-A2-IR</td><td rowspan=1 colspan=1>7-92</td><td rowspan=1 colspan=1>03/08/2004</td><td rowspan=1 colspan=1>Method Comparison and Bias Estimation UsingPatient Samples; Approved Guideline-SecondEdition</td></tr><tr><td rowspan=1 colspan=1>EP7-A2</td><td rowspan=1 colspan=1>7-127</td><td rowspan=1 colspan=1>05/21/2007</td><td rowspan=1 colspan=1>Interference Testing in Clinical Chemistry;Approved Guideline - Second Edition</td></tr></table>

Tosoh Bioscience, Inc.

# Linearity and Detection Limit:

Linriy wa preuytablishe r th assay undr k11. The epoabl ranhi device is $4 . 0 { - } 1 6 . 9 \%$ HbAlc.

# Calibrator and Controls:

Calibrators TosohAc Calibrator Set) and Controls (Canterbury ScientificHemoglobinAlc) are recommended for use with this device. The calibrators and controls were previously cleared under 510(k) numbers k071132 and k021484 respectively.

# Traceability

The assigned HbA1c values of the Tosoh Automated Glycohemoglobin Analyzer are certified with The National Glycohemoglobin Standardization Program (NGSP). The NGSP certification expires in one year. See NGSP website for current certification at http://www.ngsp.org.

The final reportable result is traceable to both the International Federation if Clinical Chemistry (IFCC) and the Diabetes Control and Complications Trial (DCCT). The International Federation of Clinical Chemistry (IFCC) units of mmol/mol are calculated using the Master Equation NGSP $( \% ) = 0 . 0 9 1 4 8 \mathrm { ~ x ~ }$ IFCC $( \mathrm { m m o l / m o l } ) + 2 . 5 2$ .HbAlc results are provided to the customers using two different units: NGSP equivalent units $( \% )$ and IFCC equivalent units $\mathrm { ( i n m o l / m o l ) }$ . :

# Conclusion:

The Tosoh Bioscience, Inc. Automated Glycohemoglobin Analyzer HLC-723G8 is substantially equivalent to the Roche Diagnostics Corporation, COBAS INTEGRA 800 Tina-quant HbA 1cDx Gen.2 assay (k121291) for in vitro diagnostic use for the measurement of hemoglobin Alc (HbA 1c) in whole blood specimens and to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

# Food and Drug Administration 10903 New Hampshire Avenuc Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

January 23, 2014

TOSOH BIOSCIENCE, INC.   
C/O ROBERT WICK   
6000 SHORELINE COURT   
SUITE 101   
SOUTH SAN FRANCISCO CA 94080

Re: K131580 Trade/Device Name: Automated Glycohemoglobin Analyzer HLC-723G8 Regulation Number: 21 CFR 862.1373 Regulation Name: Hemoglobin Alc Test System Regulatory Class: II Product Code: PDJ Dated: December 20, 2013 Received: December 20, 2013

Dear Mr. Wick:

We have reviewed your Section 510(k) premarket notification of intent to market the device renc bove nd have determied he devis substantially euivalent (or hendicin for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The al n ois  e  a vigodmfcturig praceabelg,  prhibitis agaistisrand adulteration.Please note:CDRH does not evaluate information related to contract liability warrantWe remnd yo, howeve, that device labelg must be truthul and not mislg.

If yur devii lass eboveito ither class  Specil nrols)rclass I MA), it may be subject to additional controls.Existing major regulations affecting your device can be fond inhe ode  Federal Regulations, Tite , arts 800 to 8. In addition, F may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting o medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http:/www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address htp://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Courtney H. Lias -S

Courtncy H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Deviccs and Radiological Health

510(k) Number (if known) k131580

Device Name Automated Glycohemoglobin Analyzer HLC-723G8

# PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

# This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

Theburn tme or h colection noation is etated toverage7hours pe esponseclude time to review instructions, earch existing data sources, gather and maintain the data needed and coplee and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."